Petros Pharmaceuticals Inc.
13F holders, Q3 2024 (September 30)11holders −1
2new positions
2sold out
$0.36avg. 13F price*
At the end of Q3 2024, 11 institutions reported holding Petros Pharmaceuticals Inc. in their 13F filings, down 1 from Q2 2024. 2 opened new positions and 2 sold out. The largest holders were UBS Group AG ($16K), Geode Capital Management, LLC ($13K) and Two Sigma Securities, LLC ($12K).
- Company
- Petros Pharmaceuticals Inc.
- CUSIP
- 71678J209
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $16K |
| Exits | 2 | $32K |
All 13F filers, Q2 2024 → Q3 2024: 51,586 shares bought and 91,877 shares sold, net −40,291 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| UBS Group AG | 0.00% | New | 44,221 | $16K |
| Geode Capital Management, LLC | 0.00% | Add +23.5% | 37,517 | $13K |
| Two Sigma Securities, LLC | 0.00% | Reduce -40.1% | 32,284 | $12K |
| Vanguard Group Inc. | 0.00% | No change | 31,811 | $11K |
| BlackRock, Inc. | 0.00% | — | 16,128 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -0.6% | 3,255 | $1K |
| National Bank of Canada | 0.00% | No change | 313 | $112 |
| Osaic Holdings, Inc. | 0.00% | New | 200 | $72 |
| Group One Trading LLC | 0.00% | No change | 79 | $28 |
| Bank of America Corp. | 0.00% | Add +33.3% | 72 | $26 |
| Morgan Stanley | 0.00% | No change | 19 | $7 |
"% of holder's portfolio" is PETROS PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Petros Pharmaceuticals Inc. the manager owns.